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Cisplatin nanocapsules represent a novel lipid formulation of the anti-cancer drug cis-diamminedichloroplatinum(II) (cisplatin), in which
nanoprecipitates of cisplatin are coated by a phospholipid bilayer consisting of a 1:1 mixture of zwitterionic phosphatidylcholine (PC) and
negatively charged phosphatidylserine (PS). Cisplatin nanocapsules are characterized by an unprecedented cisplatin-to-lipid ratio and exhibit
increased in vitro cytotoxicity compared to the free drug [Nat. Med. 8, (2002) 81]. In the present study, the stability of the cisplatin
nanocapsules was optimized by varying the lipid composition of the bilayer coat and monitoring in vitro cytotoxicity and the release of
contents during incubations in water and in mouse serum. The release of cisplatin from the PC/PS (1:1) nanocapsules in water increased with
increasing temperature with a t1/2 of 6.5 h at 37 jC. At 4 jC, cisplatin was retained in the nanocapsules for well over 8 days. Replacement of
PS by either phosphatidylglycerol or phosphatidic acid revealed that nanocapsules prepared of PS were more stable, which was found to be
due to the ability of PS to form a stable cisplatin–PS coordination complex. Mouse serum had a strong destabilizing effect on the cisplatin
nanocapsules. The PC/PS formulation lost over 80% of cisplatin within minutes after resuspension in serum. Incorporation of poly(ethylene
glycol 2000) (PEG)-derivatized phosphatidylethanolamine and cholesterol in the bilayer coat extended the lifetime of the cisplatin
nanocapsules in mouse serum to almost an hour. The results demonstrate that specificity in the interaction of cisplatin with anionic
phospholipids is an important criterium for the formation and stability of cisplatin nanocapsules.
D 2004 Elsevier B.V. All rights reserved.Keywords: Cisplatin; Nanocapsule; Lipid formulation; Anionic phospholipid; Stability; Drug delivery1. Introduction
The anticancer drug cis-diamminedichloroplatinum II
(cisplatin) is commonly used in the treatment of a variety
of malignancies including genitourinary, head and neck, and
non-small-cell lung cancers [1–3]. There is strong evidence
that the nuclear DNA is the most important target of
cisplatin [4]. The DNA–cisplatin adducts formed interfere
with transcription and/or replication, eventually leading to
cell death. The clinical use of cisplatin is impeded by toxic
side effects such as nephrotoxicity, peripheral neuropathy,
and ototoxicity [5,6]. Failure of treatment is often caused by
the development of resistance to cisplatin [7]. Another0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2004.03.002
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E-mail address: a.i.p.m.dekroon@chem.uu.nl (A.I.P.M. de Kroon).drawback of cisplatin is its rapid inactivation due to com-
plexation with plasma and tissue proteins [8].
One approach to reduce the toxic side effects and to
increase the therapeutic index of cisplatin is encapsulation
in liposomes. Several liposomal formulations of cisplatin
have been developed [9–11], the most recent being SPI-
077, in which cisplatin is enclosed in pegylated (‘‘stealth’’)
liposomes consisting of hydrogenated soy phosphatidyl-
choline (PC), cholesterol, and polyethylene glycol (PEG)-
derivatized distearoylphosphatidylethanolamine [12,13].
SPI-077 liposomes were reported to be stable in plasma,
to have a prolonged circulation time, and to exhibit
increased efficacy against tumors and reduced toxicity
compared to free cisplatin [12,14]. However, in the clinical
phase I–II studies carried out so far, no antitumor efficacy
of SPI-077 was observed (see, e.g. Refs. [15,16]). It
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the limiting factor of conventional liposomal cisplatin
formulations [17]. The low solubility of cisplatin in water,
resulting in low encapsulation efficiencies in liposomes,
has so far hampered the development of an effective lipid
formulation of cisplatin.
Recently, we reported a new method for the encapsula-
tion of cisplatin in a lipid formulation [18]. The method
takes advantage of the limited solubility of cisplatin in water
and produces cisplatin nanocapsules, bean-shaped nano-
precipitates of cisplatin coated by a lipid bilayer. The
nanocapsules represent a novel lipid formulation of cisplatin
characterized by an unprecedented cisplatin-to-lipid ratio
and exhibiting strongly improved cytotoxicity against tumor
cells in vitro as compared to the free drug. The formation of
the nanocapsules critically depends on the presence of
negatively charged phospholipids and positively charged
aqua-species of cisplatin [18].
The present study is focused on the stability of
cisplatin nanocapsules and its dependence on the lipid
composition of the bilayer coat. The release of cisplatin
from cisplatin nanocapsules composed of several different
lipid compositions was followed during incubations in
vitro in water and in serum. Furthermore, the influence
of the nature of the anionic phospholipid head group and
of the acyl chain composition on the formation, the
cisplatin-to-lipid ratio and the in vitro cytotoxicity of
cisplatin nanocapsules are reported. For the purpose of
long-term storage, the effect on the nanocapsules of
lyophilization and rehydration was examined. Coating
of the surface of liposomes with PEG is a popular
strategy to increase the stability and circulation time of
liposomes [19,20]. Following that strategy, the effect of
PEG on the stability of the cisplatin nanocapsules was
studied by incorporating PEG conjugated to phosphati-
dylethanolamine (DSPE-PEG2000).2. Materials and methods
2.1. Materials
Cisplatin, K2PtCl6, and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[poly (ethylene glycol)2000]
(DSPE-PEG2000) were obtained from Sigma (St.
Louis, MO). 1,2-Dioleoyl-sn-glycero-3-phospho-
choline (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphate
(DOPA), 1,2-dioleoyl-sn-glycero-3-phosphoglycerol
(DOPG), 1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPS),
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoserine (DSPS), phosphati-
dylinositol (PI) from soy bean, egg sphingomyelin, and
cholesterol were all purchased from Avanti Polar Lipids
Inc., (Birmingham, AL). Mouse serum was purchased from
Harlan (Horst, The Netherlands). All other chemicals were
analytical grade.2.2. Preparation of cisplatin nanocapsules
Cisplatin was dissolved in water and subsequently incu-
bated overnight in the dark at 37 jC to ensure full equili-
bration. Cisplatin nanocapsules were prepared by hydrating
dry lipid films (1.2 Amol) consisting of mixtures of lipids in
molar ratios as indicated, with 1.2-ml 5 mM cisplatin in
water at 37 jC for 30 min, followed by 10 freeze-thaw
cycles using ethanol/dry-ice ( 70 jC) and a water bath at
37 jC [18]. The resulting suspension was centrifuged at low
speed (4 min at 2100 rpm) in an Eppendorf centrifuge to
collect the nanocapsules in the pellet and remove multi-
lamellar liposomes (MLV) and free cisplatin. Subsequently
the nanocapsules were washed by resuspension in 1 ml of
water and centrifugation as above. Using a lipid mixture of
DOPC/DOPS 1:1, typically 30% of cisplatin and 15% of
phospholipid phosphorus were recovered in the nanocapsule
pellet.
2.3. Retention of cisplatin in nanocapsules
In order to characterize the stability of nanocapsules with
different phospholipid compositions, the nanocapsules were
resuspended at a phospholipid phosphorus concentration of
0.25 mM in water or in mouse serum. Aliquots (150 Al) of
the suspension were incubated at 37 jC unless indicated
otherwise. At appropriate time points the aliquots were
centrifuged at 20,000 g for 4 min at 20 jC, the superna-
tant was analysed for Pt-content by non-flame atomic
absorption spectroscopy (NFAAS), and this was related to
the total Pt-content of the suspension (100%). Some of the
preparations were lyophilized, stored and rehydrated after
different periods of time. After centrifugation at 20,000 g
for 4 min at 20 jC, supernatants of the rehydrated nano-
capsules were analysed for Pt-content.
2.4. Electron microscopy (EM)
Cisplatin nanocapsules were visualised by negative stain-
ing. A suspension of nanocapsules was transferred to a
carbon-coated grid, dried and stained with 4% (w/v) of
uranyl acetate for 45 s [21]. The specimens were observed
with a Philips CM10 electron microscope at an accelerating
voltage of 80 kV.
2.5. In vitro cytotoxicity assay
Cytotoxicity was assayed as described [18]. Briefly,
human IGROV-1 ovarian tumor cells [22] were grown on
plastic dishes (Costar, Cambridge, MA) in RPMI (Gibco,
Glasgow, UK) supplemented with 25 mM HEPES, 10% (v/
v) fetal calf serum (FCS; Gibco) and 100 units/ml each of
penicillin and streptomycin (Gibco). Approximately 1000
tumor cells were seeded per well in a 96-well microtiter
plate in 200-Al growth medium. After 48 h the cisplatin
formulations were added at the concentrations indicated (in
Fig. 2. Release of cisplatin from lyophilized cisplatin nanocapsules (DOPC/
DOPS 1:1) upon rehydration. Lyophilized nanocapsules were stored in the
dark for the times indicated at 4 jC (white columns) and at room
temperature (black columns). After rehydration, nanocapsules were
centrifuged and the Pt-content of the supernatant was determined and
normalized to the total Pt-content of the suspension.
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bated for 5 days at 37 jC. Prior to administration to the
cells, the lipid formulations of cisplatin in water had been
diluted in RPMI without FCS to a Pt concentration of 233
AM. Tumor cell growth inhibition induced by cisplatin was
determined using the sulforhodamine B (SRB) assay [23].
The data were fitted to a sigmoidal dose response curve
(variable slope) using GraphPad Prism (GraphPad Software,
San Diego, CA).
2.6. Other methods
Pt-contents were quantified by non-flame atomic ab-
sorption spectroscopy (NFAAS) on a SpectrAA-400 Zee-
man spectrometer (Varian, Palo Alto, CA), using a
modifier solution of 0.5% Triton X-100 in water, and
K2PtCl6 as a standard [24]. Phospholipid contents were
determined by phosphate (Pi) analysis after destruction
with perchloric acid [25]. Complex formation of cisplatin
with DOPS was analyzed as described [26]. The half-life
of the nanocapsules was calculated from the apparent
first order rate constant of the cisplatin release (k), which
was obtained by fitting the time dependent release of
cisplatin to:
RðtÞ ¼ Rð0Þ þ RðmaxÞð1 ektÞ ð1Þ
with R(t) the release of cisplatin at time t, R(0) the release at
time zero, R(max) the maximal release obtained, and t the
time of the incubation.Fig. 1. Temperature dependence of the kinetics of release of cisplatin from
nanocapsules prepared of DOPC/DOPS (1:1) upon incubation in water at
4 jC (o), 25 jC (E), and 37 jC (n). After centrifugation the Pt-content of
the supernatant was determined and normalized to the Pt-content of the
suspension of cisplatin nanocapsules before centrifugation. Data from three
(4, 25 jC) or four (37 jC) independent experiments were averaged with the
standard deviation never exceeding 0.05.3. Results
3.1. Stability in water
We previously showed that hydration of a dry lipid film
composed of equimolar amounts of DOPC and DOPS with
an aqueous solution of 5 mM cisplatin followed by 10
freeze-thaw cycles yields cisplatin nanocapsules that can be
isolated by sucrose gradient centrifugation [18]. Here, we
applied a less laborious version of the protocol, in which the
nanocapsules are collected by low speed centrifugation
rather than by gradient centrifugation. The preparation of
nanocapsules obtained at the optimal centrifugation rate (see
Section 2) is characterized by a cisplatin-to-lipid (Pt/Pi) ratio
of 11F 2 (n = 9), which translates into 3.3 mg cisplatin/
Amol phospholipid, and is comparable to that obtained with
the original protocol [18].
The release of cisplatin from DOPC/DOPS (1:1) nano-
capsules was examined upon incubation in water at different
temperatures (Fig. 1). At 4 jC, there is hardly any release
and 90% of the cisplatin initially present in the nanocapsules
is retained for at least 200 h. Increasing the incubation
temperature leads to the release of f 75% of cisplatin from
the nanocapsules, with the rate of release depending on the
temperature. By fitting the kinetics of release to a mono-
exponential, half-life values for cisplatin retention of 6.5 h at
37 jC and 28 h at 25 jC were calculated.
We employed lyophilization of nanocapsules followed by
hydration in order to evaluate the possibility to store the
formulation in the freeze-dried state, which could be useful
for future clinical use. Upon rehydration of lyophilized
DOPC/DOPS (1:1) cisplatin nanocapsules, some 60% of
the originally encapsulated cisplatin is recovered in the low
speed pellet, irrespective of the time and temperature of
storage (Fig. 2). The cytotoxicity of the rehydrated lyoph-
ilized formulation is similar to that of the standard prepara-
tion (data not shown). The nanocapsules before and after
lyophilization and rehydration were compared by electron
Table 1
Lipid dependence of the formation of cisplatin nanocapsules
Lipid composition (molar ratio) Formation of
nanocapsules
Pt/Pi ratio
aF S.D.
DOPC/DOPS, (1:1) + 11F 2 (n= 9)
DOPC/DOPG, (1:1) + 16F 2 (n= 4)
DOPC/DOPA, (1:1) + 12F 4 (n= 4)
DOPC/PI, (1:1) 
DSPC/DSPS, (1:1) 
DOPC/DSPS, (1:1) 
DSPC/DOPS, (1:1) F 1.2F 0.1 (n= 3)
DSPC/DOPC/DOPS, (1:1:2) + 3.5F 0.7 (n= 3)
DOPC/DOPS/chol/DSPE-PEG,
(27:27:40:6)
+ 12F 3 (n= 7)
a The Pt/Pi molar ratio of the nanocapsule pellet is presented as
averaged value from n experiments (F S.D.).
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population of elongate, bean-shaped particles with an aver-
age width of 45F 15 nm and a length in the range of 50–
150 nm (Fig. 3A), as described previously [18]. The
thickness of the bright layer surrounding the dark area
was estimated to be between 5 and 6 nm, which corresponds
to the size of a single bilayer. The rehydrated lyophilized
samples revealed particles with shapes and sizes similar to
those seen before freeze-drying (compare Fig. 3A and B).
3.2. Lipid specificity of nanocapsule stability
Negatively charged lipids were found to be essential for
the formation of cisplatin nanocapsules [18]. Cisplatin nano-
capsules prepared of equimolar mixtures of DOPC and
several anionic phospholipids were tested for encapsulation
efficiency, stability in water and cytotoxicity. Replacement
of DOPS by either DOPA or DOPG produced nanocapsules
in similar yields (not shown) and with similar Pt/Pi ratios
(Table 1). However, hydration in 5 mM cisplatin of mixtures
of DOPC/PI in various ratios (from 1:1 to 9:1), followed by
freezing and thawing, did not yield nanocapsules, demon-
strating specificity for the nature of the anionic lipid in the
nanocapsule formation process. The stability in water of
nanocapsules prepared from DOPC/DOPA and from DOPC/
DOPS does not significantly differ (Fig. 4). In contrast,Fig. 3. Negative stain electron micrographs of cisplatin nanocapsules
prepared of DOPC/DOPS 1:1 before (A) and after lyophilization and
rehydration (B). The scale bars reflect 100 nm.replacing DOPS or DOPA by DOPG leads to a dramatic
decrease of the half-life value for cisplatin retention from 6.5
h to 20 min, again pointing to specificity in the role played by
the anionic phospholipid. Within 3 h, all cisplatin is released
from DOPC/DOPG nanocapsules (Fig. 4). Fig. 5 shows the
growth inhibition of human ovarian IGROV-1 tumor cells
induced by cisplatin nanocapsules prepared from different
negatively charged phospholipids. The DOPC/DOPG and
DOPC/DOPA formulations display approximately similar
cytotoxic activities as free cisplatin with IC50 values around
0.4 AM, suggesting that cisplatin rapidly leaks from these
formulations in cell culture medium. The DOPS-containing
formulation exhibits increased cytotoxic activity, with an
IC50 value 1 order of magnitude lower than that of free
cisplatin (cf. Ref. [18]).Fig. 4. Time course of release of cisplatin from cisplatin nanocapsules
prepared from DOPC/DOPG 1:1 (E), DOPC/DOPA 1:1 (n) and DOPC/
DOPS 1:1 (o) upon incubation in water at 37 jC. After centrifugation, the
Pt-content of the supernatant was determined and normalized to the
Pt-content of the suspension of cisplatin nanocapsules before centrifuga-
tion. Data from four independent experiments were averaged with the
standard deviation never exceeding 0.05.
Fig. 6. Time course of release of cisplatin from cisplatin nanocapsules with
varying initial contents of PS–cisplatin complex, obtained by pre-
incubating the DOPC/DOPS (1:1) lipid film in 5 mM cisplatin for 0 min
(o), 30 min (z), and 24 h (n) prior to the freeze-thaw cycles. A pre-
incubation time of 0 min was obtained by hydrating the lipid film in 0.6-ml
water, and adding 0.6-ml 10 mM cisplatin just before the freeze-thaw
cycles. Immediately after the freeze-thaw cycles and the wash step,
nanocapsules were incubated in water at 37 jC. After centrifugation at the
time points indicated, the Pt-content of the supernatant was determined and
normalized to the Pt-content of the suspension of cisplatin nanocapsules
before centrifugation.
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and DOPC/DOPG nanocapsules may be due to the ability of
PS but not PG to form a stable coordination complex with
cisplatin [26]. To investigate whether the presence of the PS–
cisplatin complex affects the release of cisplatin from nano-
capsules, the content of PS–cisplatin complex of the nano-
capsules at the start of the release experiment was varied. This
was accomplished by varying the time of hydration of the
lipid film in 5 mM cisplatin, prior to the freeze-thaw cycles.
Analysis by thin layer chromatography (data not shown)
revealed that the content of PS–cisplatin complex present
at the start of the release experiment (expressed as percentage
of total phospholipids) increased from 10% after 0-min
hydration via 20% after 30-min hydration to 45% after 24
h of hydration in the presence of 5mM cisplatin, in agreement
with our published results [26]. As shown in Fig. 6, the
retention of cisplatin is prolonged as the pre-incubation with
cisplatin is extended from 0 min up to 24 h. We conclude that
the nanocapsules are stabilized by the presence of the PS–
cisplatin coordination complex in the bilayer coat.
In exploring other ways to improve the stability, cisplatin
nanocapsules were prepared of lipid mixtures containing
lipids with saturated acyl chains, which have been com-
monly used in liposomal formulations of cisplatin [12].
Application of the standard procedure to equimolar mixtures
of DSPC and DSPS or DOPC and DSPS failed to generate
nanocapsules. A 1:1 mixture of DSPC and DOPS did yield a
low speed pellet, albeit with an apparently tenfold lower
cisplatin-to-lipid ratio, compared to DOPC/DOPS (1:1)
nanocapsules (Table 1), consistent with co-pelleting of
‘‘empty’’ liposomes. The rate of leakage of cisplatin from
the DSPC/DOPS (1:1) formulation was strongly reduced
compared to that of DOPC/DOPS nanocapsules (half-life
values of f 25 versus 6.5 h). The cisplatin-to-lipid ratio
(Table 1) and the stability in water of a DSPC/DOPC/DOPSFig. 5. Cytotoxicity of several cisplatin nanocapsule formulations towards
IGROV-1 human ovarian carcinoma cells. The growth inhibition in
response to increasing concentrations of cisplatin is shown for cisplatin
nanocapsules prepared from DOPC/DOPS 1:1 (E), DOPC/DOPA 1:1 (n),
DOPC/DOPG 1:1 (z), DOPC/DOPS/cholesterol/DSPE-PEG 27:27:6:40
(5), and compared to that in response to conventional cisplatin (o). For
experimental conditions, see Section 2.(1:1:2) formulation were found to be intermediate between
the DOPC/DOPS and DSPC/DOPS formulations. The in-
troduction of DSPC in the nanocapsule formulation did not
improve the efficacy of the nanocapsules in vitro, in the
cytotoxicity assay (data not shown).
3.3. Stability in mouse serum
Fig. 7 shows the destabilizing effect of mouse serum on
the nanocapsules. Resuspension of the standard DOPC/
DOPS (1:1) nanocapsules in mouse serum leads to the
almost instantaneous release of virtually all cisplatin. Cen-
trifugation of such samples failed to produce a pellet. The
ability of cholesterol to reduce the membrane permeability
is well established [27,28]. For this reason, most liposomes
used for drug delivery contain cholesterol at a concentration
around 40 mol% (reviewed in Ref. [29]). Further stabiliza-
tion can be achieved by the incorporation of both cholesterol
and sphingomyelin, which form intermolecular hydrogen
bonds [30]. However, the incorporation of cholesterol at
40% (mol/mol) with respect to total lipid, with or without
the concomitant substitution of DOPC by sphingomyelin
(not shown), did not affect the half-life value of cisplatin
retention of DOPC/DOPS (1:1) nanocapsules in water (data
not shown), nor in mouse serum (Fig. 7).
Conjugation of PEG polymer to the membrane surface of
liposomes is known to provide a steric barrier against
protein binding, thus stabilizing and extending the circula-
tion time of liposomes [19,29]. Incorporation of 6 mol%
DSPE-PEG into DOPC/DOPS/cholesterol (3:3:4) nanocap-
sules significantly improves the stability in mouse serum,
Fig. 7. (A) Time course of release of cisplatin from cisplatin nanocapsules
prepared from DOPC/DOPS 1:1 (.), DOPC/DOPS/cholesterol 3:3:4 (5),
and DOPC/DOPS/cholesterol/DSPE-PEG 27:27:40:6 (z) upon incubation
in mouse serum at 37 jC. After centrifugation the Pt-content of the
supernatant was determined and normalized to the Pt-content of the
suspension before centrifugation. Data from four independent experiments
were averaged with the standard deviation never exceeding 0.05. (B)
Negative stain electron micrograph of cisplatin nanocapsules composed of
DOPC/DOPS/cholesterol/DSPE-PEG 27:27:40:6. The scale bar reflects
100 nm.
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the first few minutes, 40% of the cisplatin leaked out and
after 75 min a loss of 85% was found (Fig. 7). Increasing the
DSPE-PEG2000 content of the nanocapsules from 6 to 10
mol% of total lipids, did not further delay the release of
contents. When the content of DSPE-PEG2000 is further
increased, the nanocapsules become less stable (data not
shown). Increasing the amount of the cisplatin–PS complex
present at the start of the incubation in serum up to 45%
(leaving 5% PS) did not significantly improve stability
either (not shown). Cisplatin nanocapsules prepared from
DOPC/DOPS/cholesterol/DSPE-PEG2000 exhibit the char-
acteristic Pt/Pi ratio of around 11 (Table 1), and are
morphologically indistinguishable from their DOPC/DOPS
counterparts, as judged by negative stain EM (compare Figs.
3A and 7B). The incorporation of DSPE-PEG2000 and
cholesterol in the formulation increased the in vitro cyto-
toxicity of the nanocapsules, compared to that of the DOPC/
DOPS nanocapsules (Fig. 5).4. Discussion
Cisplatin nanocapsules constitute a new lipid formulation
of the anticancer drug cisplatin, in which a nanoprecipitate
of the drug is covered by a single phospholipid bilayer
consisting of an equimolar mixture of DOPC and DOPS
[18]. In this study the stability of the cisplatin nanocapsules
upon incubation in water and in serum was investigated, in
particular its dependence on the lipid composition of the
bilayer coat. For this purpose we simplified the preparation
protocol (see Section 3).
The formation of nanocapsules critically depends on the
presence of negatively charged phospholipids that have been
proposed to electrostatically interact with the positively
charged aqua-species of cisplatin [18]. When negatively
charged DOPS in the original formulation was replaced by
DOPG or DOPA, nanocapsules were obtained in similar
yields and with similar encapsulation efficiencies. Substitu-
tion of DOPS by (soy bean) PI did not yield nanocapsules,
even though the affinities of binding of positively charged
cisplatin species to large unilamellar vesicles composed of
DOPS and PI are similar [31]. We conclude that electrostatic
interaction by itself is not sufficient for nanocapsule forma-
tion, and speculate that the inositol headgroup of PI interferes
with the interaction between cisplatin and negatively charged
phospholipids required for the formation of nanocapsules.
The DOPC/DOPS cisplatin nanocapsules released their
contents in a temperature-dependent way upon resuspension
in water. While stable at 4 jC, they lost about 75% of their
contents with a half-time of 6.5 h at 37 jC. In contrast, the
DOPC/DOPG formulation rapidly released all of its con-
tents at 37 jC. Since PS can form a stable coordination
complex with cisplatin whereas PG cannot [26], these
results pointed to a role for the cisplatin–PS complex in
nanocapsule stability. By varying the content of cisplatin–
PS complex at the start of the release experiment, we were
indeed able to show that the complex reduces the rate of
release of contents (Fig. 6). Conceivably, the initially
electrostatic interaction of the solid core of the nanocapsules
with the bilayer is stabilized as the cisplatin–PS coordina-
tion complex forms. In addition, complex formation may
influence the permeability properties of the bilayer coat by
affecting the acyl chain order.
Interestingly, the kinetics of cisplatin release in water of
the DOPC/DOPA formulation were similar to those of
DOPC/DOPS, suggesting that complex formation may also
occur between cisplatin and PA. Analysis by thin layer
chromatography of lipid extracts of DOPC/DOPA nano-
capsules indeed showed the appearance of new spots
originating from the cisplatin–PA interaction (our unpub-
lished results), in agreement with this supposition. Unlike
the DOPC/DOPS formulation, the DOPC/DOPA formula-
tion did not exhibit increased cytotoxicity towards IGROV-1
cells compared to free cisplatin. This would indicate that the
stabilizing effect provided by the putative cisplatin–PA
complex in water does not withstand cell culture medium.
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nanocapsule formation and stability with PI < PG< PA=PS
be understood? The stabilizing role of complex formation
between PS and cisplatin and PA and cisplatin has already
been alluded to. It is tempting to speculate that the differ-
ence between PI and PG in nanocapsule formation origi-
nates from the different number of hydroxyl groups present
in the headgroup. In this scenario, the strongly hydrated
hydroxyl groups would influence the interaction between
the positively charged cisplatin aqua-species and the nega-
tively charged phosphate group of PI such that the formation
of nanocapsules is abolished.
Based on the literature on stabilization of liposomal
formulations of cisplatin and other drugs [12,29], a number
of lipid compositions were tested for their ability to improve
the stability of the cisplatin nanocapsules. A (partial) re-
placement of DOPC by saturated DSPC, which is common-
ly used in liposomal formulations of drugs, reduced the rate
of leakage of cisplatin from the nanocapsules in water.
However, it did not improve the in vitro cytotoxicity
properties and it reduced the yield of nanocapsules. The
latter indicates that the fluidity of the bilayer coat is another
constraint for nanocapsule formation. The introduction of
cholesterol up to 40 mol% is known to increase the stability
of liposomes carrying drugs and to prolong their circulation
time upon intravenous administration, with sphingomyelin
having an added effect [19,29]. However, cholesterol with
or without sphingomyelin did not improve the stability of
the cisplatin nanocapsules, neither in water nor in serum.
The positive effect of the cisplatin–PS coordination
complex on nanocapsule stability on the one hand, and
the deleterious effect of gel state phospholipids on their
formation on the other, together indicate that it is crucial that
the surrounding bilayer has the flexibility to tightly cover
the irregular surface of the cisplatin nanoprecipitate, a
condition not met by saturated phospholipids. Using solid
state NMR, the molecular order of the bilayer coat of
cisplatin nanocapsules is being addressed (V. Chupin et
al., manuscript in preparation).
Given the special architecture of the nanocapsules and
the constraints imposed on the composition of the lipid coat,
it is remarkable that suspensions of cisplatin nanocapsules
can be lyophilized and rehydrated to yield a preparation of
nanocapsules still containing 60% of the amount of cisplatin
initially enclosed, and without loss of efficacy in the in vitro
cytotoxicity assay. Although the loss of 40% of the contents
is undesirable from the point of view of future clinical
applications, these results do illustrate the stability in water
of the active nanocapsules.
The stability of the nanocapsules in serum was investi-
gated in view of a possible future clinical application. Upon
resuspension in mouse serum, the DOPC/DOPS nanocap-
sules with or without cholesterol immediately collapsed.
The presence of the negatively charged PS, a prerequisite
for the formation of nanocapsules, is most likely the cause
for the instability in serum. Although part of the PS reactswith cisplatin to form the neutral cisplatin–PS coordination
complex, the remaining negative surface charge [18] leads
to high affinity binding of serum proteins to the bilayer
coat, destabilizing the nanocapsules. PEG conjugated to PE
has been successfully used in liposomes as a steric barrier
against plasma protein binding and clearance from the
circulation [20]. Whereas incorporation of 5 mol% DSPE-
PEG effectively shields neutral liposomes composed of PC
and cholesterol, including the liposomal cisplatin formula-
tion SPI-077 [12], liposomes containing PS are more
rapidly cleared from the circulation [32], and require
elevated levels of DSPE-PEG2000 [33]. A recent report
shows that as much as 15 mol% DSPE-PEG2000 is
required for protecting liposomes containing 10 mol% PS
in the blood circulation [34].
Upon incorporation of 6 mol% DSPE-PEG2000 into
DOPC/DOPS/cholesterol (3:3:4), cisplatin nanocapsules
were obtained with a yield, Pt/Pi ratio, and morphology
indistinguishable from the original DOPC/DOPS nanocap-
sules. The stability of the cisplatin nanocapsules in serum
was drastically improved by incorporating 6 mol% of
DSPE-PEG2000. A further increase of the DSPE-PEG
content did not reduce but slightly enhanced the leakage
of contents, possibly by impairing the interaction between
the cisplatin core and the bilayer coat. The observed
increased cytotoxicity in vitro of the pegylated nanocapsules
compared to the DOPC/DOPS nanocapsules is most likely
due to the protection provided by DSPE-PEG against
leakage induced by the 10% FCS present in the culture
medium. The lifetime of the pegylated nanocapsules in
mouse serum was not prolonged upon decreasing the
negative surface charge by increasing the content of the
neutral PS–cisplatin complex at the expense of negatively
charged PS [18], suggesting that the surface charge is not
the limiting factor for the stability in serum.
In conclusion, the release of contents of cisplatin nano-
capsules depends on the temperature, the surrounding me-
dium, and the lipid composition of the bilayer coat.
Cisplatin nanocapsules containing 6 mol% DSPE-PEG will
serve as the starting formulation for in vivo studies address-
ing the anti-tumor efficacy of cisplatin nanocapsules in
tumor-bearing mice.Acknowledgements
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